The rating increase follows Oncocyte's Chinese distribution deal for its DetermaRx lung cancer treatment stratification test with Burning Rock Biotech.
BTIG put a $20 target price on Genetron's shares, while Canaccord Genuity is targeting $19 per share for the Chinese genomics and cancer diagnostics firm.
The investment bank cut its price target on Quest's shares and noted recently passed legislation that it believes will put pricing pressure on the company.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
The investment banks cited the company's access to proprietary technology and the potential $5 billion market for Exagen's testing options as reasons for its Outperform rating.